Skip to Content

Arno Therapeutics Inc ARNI

Morningstar Rating
$0.00 0.00 (42.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ARNI is trading at a 43% discount.
Price
$0.00
Fair Value
$9.57
Uncertainty
Extreme
1-Star Price
$4.21
5-Star Price
Economic Moat
Fbhvrq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARNI is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
/
Market Cap
$2,862.29
Volume/Avg
350 / 350

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
4

Valuation

Metric
ARNI
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
ARNI

Financial Strength

Metric
ARNI
Quick Ratio
1.39
Current Ratio
1.52
Interest Coverage
−323.28
Quick Ratio
ARNI

Profitability

Metric
ARNI
Return on Assets (Normalized)
−708.63%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ARNI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWqtprgpyKrfx$571.0 Bil
VRTX
Vertex Pharmaceuticals IncXdwlmnrTchwnsc$107.8 Bil
REGN
Regeneron Pharmaceuticals IncDvxgjxpcmLdjvd$106.1 Bil
MRNA
Moderna IncDnbgsnklMgqyb$42.3 Bil
ARGX
argenx SE ADRBhmfqwlGtxwx$23.7 Bil
BNTX
BioNTech SE ADRByccfpldsRxc$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRyvyyxmHzxgr$19.4 Bil
BMRN
Biomarin Pharmaceutical IncKwltxxslJqqymg$16.7 Bil
RPRX
Royalty Pharma PLC Class AJcnfdlbrRcfyds$13.6 Bil
INCY
Incyte CorpKlrmtxtypDtzgyv$12.8 Bil

Sponsor Center